Strategies to tackle RAS-mutated metastatic colorectal cancer

The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, se...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:ESMO Open
Main Authors: Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2021
Teme:
Review
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8167159/
https://ncbi.nlm.nih.gov/pubmed/34044286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100156
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki